VBI Vaccines, Inc. – (NASDAQ:VBIV) CEO Jeff Baxter bought 10,000 shares of VBI Vaccines stock in a transaction on Tuesday, December 12th. The stock was acquired at an average cost of $3.89 per share, with a total value of $38,900.00. Following the acquisition, the chief executive officer now owns 140,646 shares in the company, valued at approximately $547,112.94. The purchase was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link.
Jeff Baxter also recently made the following trade(s):
- On Tuesday, November 28th, Jeff Baxter acquired 15,000 shares of VBI Vaccines stock. The stock was purchased at an average cost of $4.75 per share, with a total value of $71,250.00.
VBI Vaccines, Inc. – (VBIV) traded up $0.08 during trading hours on Friday, reaching $4.18. The company’s stock had a trading volume of 1,223,601 shares, compared to its average volume of 252,755. VBI Vaccines, Inc. – has a twelve month low of $3.03 and a twelve month high of $6.60. The company has a debt-to-equity ratio of 0.19, a current ratio of 1.03 and a quick ratio of 0.97.
VBIV has been the subject of several research analyst reports. BidaskClub lowered VBI Vaccines from a “buy” rating to a “hold” rating in a report on Thursday, December 7th. Zacks Investment Research raised VBI Vaccines from a “sell” rating to a “hold” rating in a report on Wednesday, August 30th. BMO Capital Markets initiated coverage on VBI Vaccines in a report on Wednesday, November 15th. They issued an “outperform” rating and a $11.00 price objective for the company. Finally, Canaccord Genuity initiated coverage on VBI Vaccines in a report on Wednesday, November 1st. They issued a “buy” rating and a $10.00 price objective for the company. Two research analysts have rated the stock with a sell rating, one has given a hold rating and three have issued a buy rating to the company’s stock. The stock currently has an average rating of “Hold” and an average price target of $10.50.
About VBI Vaccines
VBI Vaccines Inc, formerly SciVac Therapeutics Inc, is a biotechnology company. The Company is engaged in developing various technologies that focus on vaccine protection. It has developed an enveloped virus like particle (eVLP) vaccine platform that allows for the design of enveloped VLP vaccines. It is involved in various projects related to human cytomegalovirus (CMV) and other antigens.
Receive News & Ratings for VBI Vaccines Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for VBI Vaccines and related companies with MarketBeat.com's FREE daily email newsletter.